Does the recession mean women are going au naturale?


Elizabeth Arden's (NASDAQ: RDEN) stock has been shellacked in the last couple of days, continuing a decline that began shortly after it reached a 52-week high of $21.79 in September 2008. RDEN has reached a nine-year low in price at $5.95.

The recent action in the stock should come as no surprise. With retail sales continuing to sour and mall traffic becoming more like Sunday services attendance on a beautiful summer day, it could hardly come as news that Elizabeth Arden would issue a negative earnings alert ahead of the company's second-quarter release of financial results scheduled for Friday.

Cosmetics and fragrances are some of the most discretionary of purchases with the widest range of price points. Consumers have the option of purchasing a less expensive brand or delaying the purchase until a better time. As a result, cosmetic products have reached a historically peak inventory level.

For Elizabeth Arden, those inventory numbers are further evidence of the earnings stress facing the company.

While cosmetics still are among the highest mark-up items in department and drug stores, the overhanging inventory will result in price slashing and production cutbacks. Earnings will suffer additional blows at Arden, as well as other cosmetic companies such as Estee Lauder (NYSE: EL) and Avon (NYSE: AVP).

Particularly disappointing at Elizabeth Arden this past season were the travel retail and distribution markets, which weakened considerably as a result of business and personal travel cutbacks. Additionally, Arden's prestige department store sales were severely reduced due to the combination of consumer reluctance and general reductions in mall traffic.

Along with the negative earnings alert issued by the company, research analysts at several firms lowered their forecasts for the company's earnings for the coming year. The adjustments in expectations came after Elizabeth Arden revised its second-quarter earnings outlook to 72 cents to 76 cents from $1 to $1.10, and reduced its forecast for the second half of the year to 1 cent to 13 cents per share.

Given the company's history of profitable operations and strong leadership from management, it is tempting to view the current price of the stock as a bargain. Caution should prevail, however.

There should be no rush to buy RDEN, as it is unlikely that there will be a turnaround in price until later this year, especially since historically the cosmetics industry generates well over 50% of its sales and an even higher percentage of its profits during the holiday season.

Jamie Dlugosch is a contributor to OptionsZone.com.

Reader Comments (Page 1 of 1)

Symbol Lookup
IndexesChangePrice
DJIA+45.1412,846.37
NASDAQ+11.652,915.53
S&P 500+5.151,347.79

Last updated: February 13, 2012: 11:16 AM

Hot Stocks

General Electric

19.03+0.155(+0.82)

Alcoa

10.37+0.08(+0.78)

Apple Inc

499.85+6.43(+1.30)

Google Inc 'A'

611.805+5.895(+0.97)

Bank of America

8.265+0.195(+2.42)

Wal-Mart Stores

62.01+0.11(+0.18)

Exxon Mobil Corp

84.07+0.27(+0.32)

Ford

12.56+0.12(+0.96)

Citigroup

33.49+0.565(+1.72)

IBM

192.27-0.15(-0.08)

Yahoo

16.095-0.045(-0.28)

Starbucks

49.22+0.40(+0.82)

Microsoft

30.555+0.06(+0.20)

Home Depot

45.74+0.41(+0.90)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329149811417 ms.